1 / 22

Presenter: Linda Barlow-Mosha MD, MPH, FAAP

The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children. Presenter: Linda Barlow-Mosha MD, MPH, FAAP Makerere University- Johns Hopkins University Research Collaboration 3rd IAS Conference July 27, 2005. Background.

riva
Download Presentation

Presenter: Linda Barlow-Mosha MD, MPH, FAAP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD, MPH, FAAP Makerere University- Johns Hopkins University Research Collaboration 3rd IAS Conference July 27, 2005

  2. Background • 90% of the 2.1million HIV infected children are in sub-Saharan Africa (UNAIDS, 2004) • Uganda has approximately 143,000 children living with HIV and 20,000 children are infected each year through mother to child transmission (MTCT) (MOH, 2001) • MU-JHU Research Collaboration has taken care of over 3000 HIV infected children since 1988 • Death occurred in 30%,66%, 75% of the children at 1, 3, and 5 years respectively (Marum et al. July 1996)

  3. Background • Benefits of HAART have not yet been fully realized in resource limited countries due to: • High cost of drugs • Limited infrastructure to monitor patients • Access has recently been increased for patients in the developing world through: • Global funds • World Bank funds-MAP • PEPFAR (President Bush’s Initiative)

  4. HAART in Uganda • Approximately 64,000 individuals on HAART (Ministry of Health,2005) • < 4000 are children under 15 years of age (Ministry of Health,2005) • Majority of the children on HAART are in a few clinics • Children are often left out because of : • Lack of infant HIV diagnostic tests • Limited appropriate drug formulation • Inadequate knowledge on ARV use in children

  5. Triomune • Fixed dose combination (d4T+3TC+NVP) - CIPLA • Reduced cost has made HAART more accessible • Clinical experience has documented satisfactory response (Laurent et al, 2004) • In Uganda a study in adults documented a decline in viral load and increase in CD4 count at 12 weeks into therapy (Oyugi et al, Bangkok 2004) • Most of the fixed dose combinations available are in tablet or capsule form and not in formulations appropriate for young children

  6. Objectives • Primary Objective • To determine the feasibility and effectiveness of a generic fixed dose combination tablet (Triomune) in HIV infected children • Secondary Objectives • To assess adherence to Triomune among HIV infected children • To document mortality rate of the children on therapy

  7. Methods • Screening • HIV infected children from perinatal trials at MU-JHU Research Collaboration and PIDC Mulago Hospital were screened using WHO criteria for antiretroviral therapy in resource limited settings and CD4 count/percent

  8. Methods • Data collection • Baseline • CBC, CD4%/CD4 abs,Viral Load • Liver function test and Renal function test • Follow up 2 years • CBC, CD4%/CD4 abs, and viral load – every 12 wks • Adherence assessment by self report and pill counts – at all routine visits • Plasma storage for later NVP resistance testing • Sub-study for NVP pharmacokinetic (n=20) • Preliminary data after 48 weeks on therapy will be presented

  9. Results • Total number screened – 164 HIV infected children • 90 enrolled • 81 given Triomune (d4T/3TC/NVP) as 1st line regime • 72 remain on Triomune • 14 are on alternative regimens • 8 due to weight <13kg • 4 due to hypersensitivity to NVP • 1 hepatitis • 1 virologic failure • 4 deaths

  10. Results At Enrollment • Median age – 5yrs (1-14yrs) • 48% female • 96% < 3rd percentile expected weight for age • 67% < 5th percentile expected height for age • 60% WHO stage II and 16% WHO stage III • 26% with CD4 percent < 5% • 67% with CD4 percent between 5-15%

  11. Results

  12. Results

  13. Baseline 12wks 24wks 36 wks 48 wks ResultsViral Load vs Baseline, 12, 24,36, & 48 Weeks Baseline VIRAL LOAD 12wks 12wks 24wks 36wks 48wks 12wks

  14. Results • 48 weeks after therapy • 96% (22/23) of children have CD4% > 15 • 83% (19/23) of children have undetectable viral load (<400copies/ml) • 42% (8/19) of the children with undetectable viral loads were NVP exposed at birth • Adherence rate – 95% in 90% of the children • Majority of children with poor adherence were on syrups

  15. Results- Toxicity and Mortality • Side Effects • skin rash - 4% (4/90) • hepatitis - 1% (1/90) • Mortality rate is 4% (4/90) • 2/4 children had an initial CD4 count less than 1% • 3/4 children were severely immuno-suppressed or WHO stage III • Causes of death include toxoplasmosis, malaria, and pneumonia

  16. Results • Treatment Failure • Defined as viral load >400 copies/ml at 48 wks • The 4 children with detectable viral loads • history of poor/fair adherence to syrups • exposure to single-dose Nevirapine at birth • baseline viral loads >750,000 copies/ml • viral rebound effect

  17. Results- Treatment Failure • 1/4 children with detectable viral loads has also shown immunologic failure to therapy

  18. Conclusions • The use of fixed dose combination in HIV infected children is feasible and effective • Triomune led to a significant increase in CD4 count and a decrease in viral load during the initial 48 weeks of therapy • Adherence is better with a fixed dose combination than syrups • We are still monitoring the effect of single-dose Nevirapine exposure on response to future NVP containing HAART regimens

  19. Acknowledgments • Elizabeth Glaser Pediatric AIDS Foundation • International Leadership Award (ILA) • Dr. Phillipa Musoke – Department of Pediatrics, Makerere University Mulago / MU-JHU Research Collaboration, Recipient of ILA • Program Staff – MU-JHU Research Collaboration • P. Ajuna, M. Luttajumwa, B. Musoke, J. Walabyeki, M. Owor, M. Mubiru, M.G. Nalubega, M. Namawejje, E. Babirekere • MU-JHU Research Collaboration • Children and their caretakers

  20. Thank You

More Related